Do analysts prefer BIAF or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ONCO or ZVSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ZVSA or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ZVSA or PPCB?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is ZVSA or PPCB more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% Propanc Biopharma N/A -151.28% -109.53%

Do analysts recommend ZVSA or GOVX?

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 30,949.47%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than ZyVersa Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ZVSA or GOVX more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% GeoVax Labs N/A -743.64% -394.74%

Do analysts recommend ZVSA or SLXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Silexion Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, ZVSA or SLXN?

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ZyVersa Therapeutics N/A N/A -$9.41M -$0.83 N/A Silexion Therapeutics N/A N/A -$11.91M -$42.47 N/A

Is ZVSA or SLXN more profitable?

ZyVersa Therapeutics' return on equity of -109.54% beat Silexion Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ZyVersa Therapeutics N/A -109.54% -43.95% Silexion Therapeutics N/A -563.11% -201.73%

ZyVersa Therapeutics (ZVSA) Competitors

$0.10 +0.00 (+3.83%)

As of 09/4/2026 01:42 PM Eastern

Compare

ZVSA vs. BIAF, ONCO, PPCB, GOVX, and SLXN

Should you buy ZyVersa Therapeutics stock or one of its competitors? ZyVersa Therapeutics's main competitors and comparable companies include bioAffinity Technologies (BIAF), Onconetix (ONCO), Propanc Biopharma (PPCB), GeoVax Labs (GOVX), and Silexion Therapeutics (SLXN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ZyVersa Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

ZyVersa Therapeutics has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ZyVersa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$6.16M	1.46	-$14.91M	-$109.45	N/A
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

In the previous week, bioAffinity Technologies had 8 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 8 mentions for bioAffinity Technologies and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 beat bioAffinity Technologies' score of -0.32 indicating that ZyVersa Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
bioAffinity Technologies	Neutral
ZyVersa Therapeutics	Neutral

1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by company insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ZyVersa Therapeutics has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -257.30%. ZyVersa Therapeutics' return on equity of -109.54% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-257.30%	-220.52%	-136.76%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

bioAffinity Technologies has a beta of -1.11, indicating that its share price is 211% less volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Summary

ZyVersa Therapeutics beats bioAffinity Technologies on 9 of the 13 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Onconetix?

Onconetix (NASDAQ:ONCO) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

ZyVersa Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat ZyVersa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
ZyVersa Therapeutics	N/A	-109.54%	-43.95%

23.9% of Onconetix shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 0.2% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Onconetix has a beta of 2.68, indicating that its stock price is 168% more volatile than the broader market. Comparatively, ZyVersa Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

ZyVersa Therapeutics has lower revenue, but higher earnings than Onconetix. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	5.52	-$14.03M	$248.12	0.00
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A

In the previous week, Onconetix had 2 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 2 mentions for Onconetix and 0 mentions for ZyVersa Therapeutics. Onconetix's average media sentiment score of 0.00 equaled ZyVersa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Onconetix	Neutral
ZyVersa Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Onconetix beats ZyVersa Therapeutics on 9 of the 12 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Propanc Biopharma?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

In the previous week, ZyVersa Therapeutics' average media sentiment score of 0.00 equaled Propanc Biopharma'saverage media sentiment score.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
Propanc Biopharma	Neutral

3.9% of ZyVersa Therapeutics shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 28.7% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ZyVersa Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ZyVersa Therapeutics' return on equity of -109.54% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Propanc Biopharma	N/A	-151.28%	-109.53%

Summary

ZyVersa Therapeutics beats Propanc Biopharma on 5 of the 9 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to GeoVax Labs?

ZyVersa Therapeutics (NASDAQ:ZVSA) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

ZyVersa Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.66, indicating that its share price is 266% more volatile than the broader market.

In the previous week, ZyVersa Therapeutics' average media sentiment score of 0.00 equaled GeoVax Labs'average media sentiment score.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
GeoVax Labs	Neutral

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 30,949.47%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than ZyVersa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by company insiders. Comparatively, 0.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ZyVersa Therapeutics has higher earnings, but lower revenue than GeoVax Labs. ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
GeoVax Labs	$2.49M	1.43	-$21.47M	-$11.34	N/A

ZyVersa Therapeutics' return on equity of -109.54% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
GeoVax Labs	N/A	-743.64%	-394.74%

Summary

GeoVax Labs beats ZyVersa Therapeutics on 7 of the 11 factors compared between the two stocks.

How does ZyVersa Therapeutics compare to Silexion Therapeutics?

ZyVersa Therapeutics (NASDAQ:ZVSA) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Silexion Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 1 mentions for Silexion Therapeutics and 0 mentions for ZyVersa Therapeutics. ZyVersa Therapeutics' average media sentiment score of 0.00 beat Silexion Therapeutics' score of -0.64 indicating that ZyVersa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
ZyVersa Therapeutics	Neutral
Silexion Therapeutics	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZyVersa Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Silexion Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

3.9% of ZyVersa Therapeutics shares are held by institutional investors. Comparatively, 11.0% of Silexion Therapeutics shares are held by institutional investors. 0.2% of ZyVersa Therapeutics shares are held by insiders. Comparatively, 0.8% of Silexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ZyVersa Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Silexion Therapeutics has a beta of -0.36, suggesting that its share price is 136% less volatile than the broader market.

ZyVersa Therapeutics' return on equity of -109.54% beat Silexion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZyVersa Therapeutics	N/A	-109.54%	-43.95%
Silexion Therapeutics	N/A	-563.11%	-201.73%

ZyVersa Therapeutics is trading at a lower price-to-earnings ratio than Silexion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZyVersa Therapeutics	N/A	N/A	-$9.41M	-$0.83	N/A
Silexion Therapeutics	N/A	N/A	-$11.91M	-$42.47	N/A

Summary

ZyVersa Therapeutics and Silexion Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get ZyVersa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVSA vs. The Competition

Export

Metric	ZyVersa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$817K	$4.01B	$7.25B	$12.92B
Dividend Yield	N/A	3.60%	2.53%	9.14%
P/E Ratio	-0.12	7.47	213.35	20.98
Price / Sales	N/A	1,346.74	625.09	95.03
Price / Cash	N/A	108.60	77.08	52.44
Price / Book	0.03	16.14	12.85	6.17
Net Income	-$9.41M	-$22.80M	$3.49B	$350.08M
7 Day Performance	-1.90%	0.31%	1.04%	-0.14%
1 Month Performance	-0.39%	8.25%	5.52%	1.02%
1 Year Performance	-26.32%	49.17%	24.39%	14.51%

ZyVersa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVSA ZyVersa Therapeutics	N/A	$0.10 +3.8%	N/A	-27.5%	$817K	N/A	N/A	2
BIAF bioAffinity Technologies	0.6161 of 5 stars	$5.06 -0.6%	N/A	-85.8%	$3.02M	$6.16M	N/A	10	News Coverage Gap Up
ONCO Onconetix	0.6864 of 5 stars	$0.63 -1.4%	N/A	-99.3%	$2.53M	$810K	0.00	12	News Coverage
PPCB Propanc Biopharma	0.3862 of 5 stars	$2.23 +108.4%	N/A	-98.0%	$2.44M	N/A	N/A	1	Gap Down High Trading Volume
GOVX GeoVax Labs	1.5338 of 5 stars	$0.72 +13.8%	$150.00 +20,820.5%	-97.4%	$2.19M	$2.49M	N/A	10	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVSA) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. BIAF, ONCO, PPCB, GOVX, and SLXN

How does ZyVersa Therapeutics compare to bioAffinity Technologies?

Summary

How does ZyVersa Therapeutics compare to Onconetix?

Summary

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Summary

How does ZyVersa Therapeutics compare to Silexion Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ZyVersa Therapeutics (ZVSA) Competitors

ZVSA vs. BIAF, ONCO, PPCB, GOVX, and SLXN

How does ZyVersa Therapeutics compare to bioAffinity Technologies?

Which has preferable valuation and earnings, BIAF or ZVSA?

Does the media prefer BIAF or ZVSA?

Do insiders & institutionals hold more shares of BIAF or ZVSA?

Is BIAF or ZVSA more profitable?

Do analysts prefer BIAF or ZVSA?

Which has more volatility and risk, BIAF or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Onconetix?

Is ONCO or ZVSA more profitable?

Do institutionals and insiders hold more shares of ONCO or ZVSA?

Which has more risk & volatility, ONCO or ZVSA?

Which has better earnings & valuation, ONCO or ZVSA?

Does the media prefer ONCO or ZVSA?

Do analysts prefer ONCO or ZVSA?

Summary

How does ZyVersa Therapeutics compare to Propanc Biopharma?

Which has preferable valuation & earnings, ZVSA or PPCB?

Does the media prefer ZVSA or PPCB?

Do institutionals and insiders have more ownership in ZVSA or PPCB?

Which has more risk & volatility, ZVSA or PPCB?

Do analysts prefer ZVSA or PPCB?

Is ZVSA or PPCB more profitable?

Summary

How does ZyVersa Therapeutics compare to GeoVax Labs?

Which has more risk & volatility, ZVSA or GOVX?

Does the media favor ZVSA or GOVX?

Do analysts recommend ZVSA or GOVX?

Do institutionals & insiders believe in ZVSA or GOVX?

Which has higher valuation and earnings, ZVSA or GOVX?

Is ZVSA or GOVX more profitable?

Summary

How does ZyVersa Therapeutics compare to Silexion Therapeutics?

Does the media prefer ZVSA or SLXN?

Do analysts recommend ZVSA or SLXN?

Do institutionals and insiders hold more shares of ZVSA or SLXN?

Which has more volatility & risk, ZVSA or SLXN?

Is ZVSA or SLXN more profitable?

Which has better earnings & valuation, ZVSA or SLXN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVSA vs. The Competition

ZyVersa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools